Wednesday, July 13, 2022

Plexium Names New Board Member

San Diego-based targeted protein degradation company Plexium said today that it has named a new member to its board of directors. The company said it appointed Brian Wong, the President and CEO of RAPT Therapeutics, to its board. Wong also previously served as Senior Vice President, Research, and Head of Immuno-Oncology at Five Prime Therapeutics and as Director in the Inflammation Disease Biology Area at Roche. Plexium is venture backed by Lux Capital and Pivotal BioVentures, The Column Group, DCVC Bio and others.